Optiscan and EMVision are among ASX healthcare companies reporting clinical milestones reached in quarterly results.

Juniper Biosciences today announced a strategic licensing agreement with Memorial Sloan Kettering Cancer Center (MSK) to ...

Juniper Biosciences today announced a strategic licensing agreement with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the development of JBS-003 (18F-fluoromisonidazole, or FMISO). This ...

The 2026 CPT® updates bring sweeping changes to radiology coding, adding advanced imaging and interventional procedure codes while refining existing descriptors. With audits intensifying and ...

Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases following earlier ...

Approval marks a major milestone in reducing gadolinium exposure while maintaining diagnostic performance, aligning with clinical guidance to use the lowest effective dose MONTREAL, April 17, 2026 ...

Abstract: Many medical applications, such as proton therapy and radiotherapy planning, require both Contrast Enhanced CT (CECT) for tumor and organ delineation and Non-Contrast Enhanced CT (NCECT) for ...

The visual nature of head and neck cancer calls for treatment strategies that will minimize toxicities related to radiation therapy. Advances in precision radiation techniques, supportive care, and ...

ABSTRACT: Objectives: Accurate assessment of neck lymphadenopathy is crucial in Oral Squamous Cell Carcinoma (OSCC) due to its prognostic significance. This study aimed to evaluate the reliability and ...

Surgeons across the country are testing a glowing nerve imaging agent that could make head and neck surgery safer. Here’s how it works. A new surgical technique is helping doctors better protect ...